These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 18824230)
1. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Agarwal A; Shen LY; Kirk AD Transpl Immunol; 2008 Nov; 20(1-2):6-11. PubMed ID: 18824230 [TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation. Weissenbacher A; Boesmueller C; Brandacher G; Oellinger R; Pratschke J; Schneeberger S Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110 [TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240 [TBL] [Abstract][Full Text] [Related]
4. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Magliocca JF; Knechtle SJ Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530 [TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Lü TM; Yang SL; Wu WZ; Tan JM Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554 [TBL] [Abstract][Full Text] [Related]
6. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. Silveira FP; Marcos A; Kwak EJ; Husain S; Shapiro R; Thai N; McCurry KR; Abu-Elmagd K; Paterson DL J Infect; 2006 Oct; 53(4):241-7. PubMed ID: 16403576 [TBL] [Abstract][Full Text] [Related]
7. Some observations on prope tolerance. Calne R; Watson CJ Curr Opin Organ Transplant; 2011 Aug; 16(4):353-8. PubMed ID: 21666472 [TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab induction in deceased donor kidney transplantation. Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271 [TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178 [TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326 [TBL] [Abstract][Full Text] [Related]
12. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of alemtuzumab in organ transplantation: current clinical status. Ciancio G; Burke GW; Warque ME; Miller J BioDrugs; 2006; 20(2):85-92. PubMed ID: 16626166 [TBL] [Abstract][Full Text] [Related]
14. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction. Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366 [TBL] [Abstract][Full Text] [Related]
15. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781 [TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation. Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198 [TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Muthusamy AS; Vaidya AC; Sinha S; Roy D; Elker DE; Friend PJ Am J Transplant; 2008 Oct; 8(10):2126-31. PubMed ID: 18828772 [TBL] [Abstract][Full Text] [Related]
18. Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant. Bhowmick M; Auckbarallee F; Edgar P; Ray A; Dasgupta S Exp Clin Transplant; 2016 Feb; 14(1):17-21. PubMed ID: 26862819 [TBL] [Abstract][Full Text] [Related]
19. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797 [TBL] [Abstract][Full Text] [Related]
20. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China. Yuan-Xin L; Ning L; You-Sheng L; Xiao-Dong N; Ming L; Jian W; Jie-Shou L Transplant Proc; 2010; 42(1):29-34. PubMed ID: 20172275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]